
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8409797/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses. Blood Advances, 2022, 6, 2107-2119.	5.2	26
2	Antiplatelet medications and risk of intracranial hemorrhage in patients with metastatic brain tumors. Blood Advances, 2022, 6, 1559-1565.	5.2	3
3	Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood, 2022, 139, 2252-2256.	1.4	7
4	Antibody and T-cell responses to SARS-CoV-2 vaccination in myeloproliferative neoplasm patients. Leukemia, 2022, 36, 1176-1179.	7.2	3
5	Predictors of thrombosis in children receiving therapy for acute lymphoblastic leukemia: Results from Danaâ€Farber Cancer Institute ALL Consortium trial 05â€001. Pediatric Blood and Cancer, 2022, 69, e29581.	1.5	6
6	Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer. Clinical Cancer Research, 2022, 28, 3356-3366.	7.0	13
7	Landscape of helper and regulatory antitumour CD4+ T cells in melanoma. Nature, 2022, 605, 532-538.	27.8	70
8	Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Science Immunology, 2022, 7, eabp8328.	11.9	40
9	Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. PLoS Medicine, 2022, 19, e1004012.	8.4	3
10	Reversal of viral and epigenetic HLA class I repression in Merkel cell carcinoma. Journal of Clinical Investigation, 2022, 132, .	8.2	10
11	Identification of prognostic factors in childhood Tâ€cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05â€001 and 11â€001. Pediatric Blood and Cancer, 2021, 68, e28719.	1.5	26
12	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discovery, 2021, 2, 54-69.	5.0	16
13	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nature Medicine, 2021, 27, 515-525.	30.7	248
14	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. Leukemia, 2021, 35, 2688-2692.	7.2	7
15	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell, 2021, 39, 380-393.e8.	16.8	27
16	Pretreatment clinical and genetic factors predict early postâ€ŧreatment mortality in fit <scp>AML</scp> patients following induction. American Journal of Hematology, 2021, 96, E259-E262.	4.1	1
17	The clinical and functional effects of <i>TERT</i> variants in myelodysplastic syndrome. Blood, 2021, 138, 898-911.	1.4	27
18	Testing for clonal hematopoiesis of indeterminate potential in breast cancer survivors Journal of Clinical Oncology, 2021, 39, e24108-e24108.	1.6	0

#	Article	IF	CITATIONS
19	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. Cancer Discovery, 2021, 11, 3048-3063.	9.4	31
20	<i>ZBTB33</i> Is Mutated in Clonal Hematopoiesis and Myelodysplastic Syndromes and Impacts RNA Splicing. Blood Cancer Discovery, 2021, 2, 500-517.	5.0	17
21	Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCl 11-001. Journal of Clinical Oncology, 2021, 39, 3496-3505.	1.6	36
22	Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network. Clinical Cancer Research, 2021, 27, 5072-5083.	7.0	10
23	Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature, 2021, 596, 119-125.	27.8	239
24	Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment. Nature Cancer, 2021, 2, 758-772.	13.2	52
25	Overall survival with warfarin vs. Iowâ€molecularâ€weight heparin in cancerâ€associated thrombosis. Journal of Thrombosis and Haemostasis, 2021, 19, 2825-2834.	3.8	8
26	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell, 2021, 184, 4969-4980.e15.	28.9	94
27	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 5395.	12.8	15
28	Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell–Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. Cancer Research, 2021, 81, 6117-6130.	0.9	10
29	Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer Journal, 2021, 11, 176.	6.2	13
30	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	7.0	0
31	Mapping the evolution of TÂcell states during response and resistance to adoptive cellular therapy. Cell Reports, 2021, 37, 109992.	6.4	37
32	High Incidence of Bleeding Found with Direct Oral Anticoagulant Use in Myeloproliferative Neoplasm Patients. Blood, 2021, 138, 3632-3632.	1.4	3
33	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	7.0	6
34	Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e122-e133.	4.6	19
35	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nature Medicine, 2020, 26, 1468-1479.	30.7	87
36	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372

#	Article	IF	CITATIONS
37	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Science Translational Medicine, 2020, 12, .	12.4	17
38	Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. Immunity, 2020, 53, 658-671.e6.	14.3	98
39	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood, 2020, 136, 3070-3081.	1.4	25
40	HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium. Pharmacogenomics, 2020, 21, 541-547.	1.3	9
41	<i>SF3B1</i> -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
42	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	30.7	488
43	Dose-adjusted enoxaparin thromboprophylaxis in hospitalized cancer patients: a randomized, double-blinded multicenter phase 2 trial. Blood Advances, 2020, 4, 2254-2260.	5.2	22
44	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	12.8	98
45	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clinical Cancer Research, 2020, 26, 2556-2564.	7.0	109
46	Anticoagulation after intracranial hemorrhage in brain tumors: Risk of recurrent hemorrhage and venous thromboembolism. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 860-865.	2.3	13
47	Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy. Scientific Reports, 2020, 10, 723.	3.3	21
48	CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica, 2020, 105, 1361-1368.	3.5	23
49	CIMAC-CIDC tissue imaging harmonization Journal of Clinical Oncology, 2020, 38, 3125-3125.	1.6	1
50	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade Journal of Clinical Oncology, 2020, 38, 5010-5010.	1.6	2
51	A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignancies. Science, 2019, 365, 599-604.	12.6	265
52	Severe CD4+ T ell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus. Transfusion, 2019, 59, 2783-2787.	1.6	5
53	Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. PLoS ONE, 2019, 14, e0218783.	2.5	9
54	Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. Pharmacogenomics, 2019, 20, 1189-1197.	1.3	7

#	Article	IF	CITATIONS
55	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer Cell, 2019, 36, 369-384.e13.	16.8	224
56	A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. Cancer Cell, 2019, 35, 283-296.e5.	16.8	71
57	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature, 2019, 570, 474-479.	27.8	86
58	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Cancer Cell, 2019, 35, 664-676.e7.	16.8	70
59	Activation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. Blood, 2019, 133, 2651-2663.	1.4	15
60	CD4+ Tâ€cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year. Transfusion, 2019, 59, 1644-1647.	1.6	7
61	Neoantigen vaccine generates intratumoral T cell responses in phase lb glioblastoma trial. Nature, 2019, 565, 234-239.	27.8	956
62	Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunology Research, 2019, 7, 100-112.	3.4	220
63	Plateletpheresis-associated lymphopenia in frequent platelet donors. Blood, 2019, 133, 605-614.	1.4	17
64	Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. American Journal of Hematology, 2019, 94, 446-454.	4.1	56
65	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195
66	Postoperative bridging anticoagulation and left ventricular assist system thrombosis. Journal of Thrombosis and Thrombolysis, 2019, 47, 57-66.	2.1	2
67	Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia. Pharmacogenomics Journal, 2019, 19, 33-41.	2.0	16
68	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. JCI Insight, 2019, 4, .	5.0	110
69	Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response. Blood, 2019, 134, 4202-4202.	1.4	1
70	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. Blood, 2019, 134, 4172-4172.	1.4	6
71	Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations. Blood, 2019, 134, 684-684.	1.4	2
72	A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood, 2019, 134, 3867-3867.	1.4	30

#	Article	IF	CITATIONS
73	Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: Results of DFCI 11-001 Journal of Clinical Oncology, 2019, 37, 10006-10006.	1.6	7
74	B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL. Blood, 2019, 134, 848-848.	1.4	0
75	T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation. Blood, 2019, 134, 680-680.	1.4	1
76	Lineage Tracing in Chronic Lymphocytic Leukemia Reveals Clones with Stable Gene Expression States That Differentially Respond to Therapy. Blood, 2019, 134, 1229-1229.	1.4	0
77	Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL. Blood, 2019, 134, 4281-4281.	1.4	0
78	MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers. Blood, 2019, 134, 1284-1284.	1.4	3
79	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). Blood, 2019, 134, 516-516.	1.4	0
80	Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias. Blood, 2019, 134, 169-169.	1.4	0
81	Recurrent Intracranial Hemorrhage and Venous Thromboembolism Following Initial Intracranial Hemorrhage in Patients with Brain Tumors on Anticoagulation. Blood, 2019, 134, 2438-2438.	1.4	0
82	Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-NaÃ ⁻ ve Patients with Relapsed or Refractory Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Multi-Center Phase 1, Two-Arm, Dose-Escalation Study. Blood, 2019, 134, 2015-2015.	1.4	3
83	Deciphering the Role of Locally Disordered DNA Methylation on CLL Development In Vivo. Blood, 2019, 134, 1737-1737.	1.4	0
84	Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical, Clinical, and Correlative Studies. Blood, 2019, 134, 2549-2549.	1.4	1
85	A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 1503. Blood, 2019, 134, 4592-4592.	1.4	0
86	PPARÎ ³ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSF. Cancer Immunology Research, 2018, 6, 723-732.	3.4	21
87	Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood, 2018, 132, 170-178.	1.4	36
88	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia, 2018, 32, 2126-2137.	7.2	48
89	Phase I trial of the mTOR inhibitor everolimus in combination with multiâ€agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27062.	1.5	48
90	Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	12.4	299

#	Article	IF	CITATIONS
91	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	28.9	113
92	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. Journal of Thrombosis and Thrombolysis, 2018, 45, 306-314.	2.1	31
93	Association of mutations with morphological dysplasia in <i>de novo</i> acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica, 2018, 103, 626-633.	3.5	20
94	Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e26952.	1.5	31
95	Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2018, 65, e27082.	1.5	0
96	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nature Medicine, 2018, 24, 679-690.	30.7	1,224
97	Microbial symbionts regulate the primary Ig repertoire. Journal of Experimental Medicine, 2018, 215, 1397-1415.	8.5	43
98	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3741-E3748.	7.1	10
99	Dynamic changes in <scp>CCL</scp> 3 and <scp>CCL</scp> 4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. British Journal of Haematology, 2018, 180, 597-600.	2.5	5
100	Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance onferring FLT3/tyrosine kinase domain/F691 mutation. Cancer, 2018, 124, 306-314.	4.1	23
101	An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Danaâ€Farber Cancer Institute ALL Consortium protocol 05â€001. Pediatric Blood and Cancer, 2018, 65, e26871.	1.5	23
102	Wrangling with <i>P</i> â€values. Pediatric Blood and Cancer, 2018, 65, e26834.	1.5	0
103	Reply to Z. Wu et al. Journal of Clinical Oncology, 2018, 36, 2657-2657.	1.6	0
104	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Journal of Clinical Oncology, 2018, 36, 942-950.	1.6	273
105	Statistics Everywhere. HemaSphere, 2018, 2, e30.	2.7	1
106	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 3094-3114.	8.5	37
107	Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Advances, 2018, 2, 529-533.	5.2	34
108	Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Advances, 2018, 2, 1449-1458.	5.2	73

#	Article	IF	CITATIONS
109	JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2018, 215, 1929-1945.	8.5	22
110	A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens. Blood, 2018, 132, 1911-1921.	1.4	44
111	Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment. Blood, 2018, 132, 825-836.	1.4	121
112	Outcome of children and adolescents with Down syndrome treated on Danaâ€Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00–001 and 05â€001. Pediatric Blood and Cancer, 2018, 65, e27256.	1.5	26
113	CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. Cancer Discovery, 2018, 8, 884-897.	9.4	53
114	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight, 2018, 3, .	5.0	39
115	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. Blood, 2018, 132, 228-228.	1.4	14
116	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	1.4	6
117	Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia. Blood, 2018, 132, 766-766.	1.4	9
118	A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma. Blood, 2018, 132, 1654-1654.	1.4	2
119	Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. Blood, 2018, 132, 796-796.	1.4	3
120	Genetic Determinants of Venetoclax Resistance in Lymphoid Malignancies. Blood, 2018, 132, 893-893.	1.4	4
121	The Benefits of TRTHing along. HemaSphere, 2018, 2, e138.	2.7	0
122	Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias. Blood, 2018, 132, 891-891.	1.4	0
123	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults. Blood, 2018, 132, 2704-2704.	1.4	0
124	Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). Blood, 2018, 132, 985-985.	1.4	0
125	Sudden Death in Sickle Cell Disease: An Assessment of Risk Factors. Blood, 2018, 132, 4929-4929.	1.4	0
126	Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults. Blood, 2018, 132, 4059-4059.	1.4	0

#	Article	IF	CITATIONS
127	Single Cell Transcriptomic Characterization of the Immune Microenvironment in Naturally Progressing Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 3112-3112.	1.4	1
128	CD4+ T-Cell Lymphopenia in Frequent Platelet Donors Who Have Ceased Platelet Donation for at Least 1 Year. Blood, 2018, 132, 2550-2550.	1.4	0
129	Safety of Direct-Acting Oral Anticoagulants Versus Enoxaparin in Patients with Primary and Metastatic Brain Tumors. Blood, 2018, 132, 2521-2521.	1.4	Ο
130	KZF-L162R Mutation Affects Splenic Mature B Cell Development and Alters Expression of Aiolos Target Genes. Blood, 2018, 132, 668-668.	1.4	0
131	Mapping the Evolution of T Cell Transcriptional States during DLI Response and Resistance Using Single-Cell Data. Blood, 2018, 132, 821-821.	1.4	0
132	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). Blood, 2018, 132, 820-820.	1.4	0
133	Potential Barriers to Clinical Trials of New Therapeutics for Myelodysplastic Syndromes: Wide Variation in Risk Definitions and Trial Enrollment Criteria. Blood, 2018, 132, 4378-4378.	1.4	Ο
134	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 1431-1431.	1.4	0
135	PRC2 Inactivation Induces Resistance to Chemotherapy-Induced Apoptosis By Upregulating the TRAP1 Mitochondrial Chaperone in T-ALL. Blood, 2018, 132, 889-889.	1.4	0
136	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	1.6	339
137	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. New England Journal of Medicine, 2017, 376, 536-547.	27.0	586
138	Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood, 2017, 129, 3379-3385.	1.4	77
139	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. Clinical Cancer Research, 2017, 23, 4680-4692.	7.0	8
140	Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 111-121.	27.0	1,738
141	<i>NPM1</i> mutation but not <i>RUNX1</i> mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. American Journal of Hematology, 2017, 92, E123-E124.	4.1	11
142	Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. Haematologica, 2017, 102, 498-508.	3.5	34
143	Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica, 2017, 102, 719-727.	3.5	33
144	LMO1 Synergizes with MYCN to Promote Neuroblastoma Initiation and Metastasis. Cancer Cell, 2017, 32, 310-323.e5.	16.8	80

#	Article	IF	CITATIONS
145	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood, 2017, 130, 2420-2430.	1.4	262
146	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8614-8619.	7.1	42
147	Analysis of <i>Fusobacterium</i> persistence and antibiotic response in colorectal cancer. Science, 2017, 358, 1443-1448.	12.6	983
148	An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547, 217-221.	27.8	2,112
149	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Research, 2017, 27, 1300-1311.	5.5	67
150	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nature Communications, 2017, 8, 2185.	12.8	148
151	Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. Oncotarget, 2017, 8, 67639-67650.	1.8	26
152	Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. Blood Advances, 2017, 1, 1645-1649.	5.2	38
153	How many mice? Design considerations for murine studies. Blood Advances, 2017, 1, 1466-1466.	5.2	1
154	Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. JCl Insight, 2017, 2, e89373.	5.0	96
155	Amino acid–insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells. Journal of Clinical Investigation, 2017, 127, 1405-1413.	8.2	23
156	Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget, 2017, 8, 43752-43767.	1.8	33
157	Fetal Erythropoiesis Is Defective in Rpl11 Heterozygous Mice and Increases in Severity in Young Animals. Blood, 2017, 130, 872-872.	1.4	0
158	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Advances, 2016, 1, 84-92.	5.2	6
159	Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicinâ€treated childhood acute lymphoblastic leukemia survivors. Cancer, 2016, 122, 946-953.	4.1	34
160	Pediatricâ€inspired therapy compared to allografting for <scp>P</scp> hiladelphia chromosomeâ€negative adult ALL in first complete remission. American Journal of Hematology, 2016, 91, 322-329.	4.1	72
161	Allogeneic transplantation is not superior to chemotherapy in most patients over 40Âyears of age with Philadelphiaâ€negative acute lymphoblastic leukemia in first remission. American Journal of Hematology, 2016, 91, 793-799.	4.1	14
162	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. Blood, 2016, 128, 2931-2940.	1.4	102

#	Article	IF	CITATIONS
163	Indications and Results of HLA-Identical Sibling Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 207-211.	2.0	97
164	<i>PD-L1</i> and <i>PD-L2</i> Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Journal of Clinical Oncology, 2016, 34, 2690-2697.	1.6	634
165	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586.	16.8	227
166	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood, 2016, 128, 1093-1100.	1.4	126
167	Gene expression–based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood, 2016, 128, 1845-1853.	1.4	83
168	The Dohner fluorescence <i>inÂsitu</i> hybridization prognostic classification of chronic lymphocytic leukaemia (<scp>CLL</scp>): the <scp>CLL</scp> Research Consortium experience. British Journal of Haematology, 2016, 173, 105-113.	2.5	66
169	Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. Nature Chemical Biology, 2016, 12, 845-852.	8.0	178
170	Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7701-E7709.	7.1	105
171	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Science Translational Medicine, 2016, 8, 350ra104.	12.4	45
172	Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunology Research, 2016, 4, 910-916.	3.4	146
173	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications, 2016, 7, 11589.	12.8	285
174	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Cancer Cell, 2016, 30, 750-763.	16.8	173
175	Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Danaâ€Farber Cancer Institute ALL Consortium Protocols (2000–2010). Pediatric Blood and Cancer, 2016, 63, 1012-1018.	1.5	69
176	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature Medicine, 2016, 22, 792-799.	30.7	322
177	MYC Immunohistochemistry to Identify MYC-Driven B-Cell Lymphomas in Clinical Practice. American Journal of Clinical Pathology, 2016, 145, 166-179.	0.7	29
178	Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncology, 2016, 2, 518.	7.1	121
179	Intracranial Hemorrhage in Patients with Primary Brain Tumors Treated with Therapeutic Enoxaparin: A Matched Cohort Study. Blood, 2016, 128, 142-142.	1.4	1
180	Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001. Blood, 2016, 128, 175-175.	1.4	11

#	Article	IF	CITATIONS
181	The Landscape of Dynamic Genetic Changes in Ibrutinib-Treated CLL. Blood, 2016, 128, 188-188.	1.4	3
182	Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 2016, 128, 2923-2923.	1.4	5
183	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. Blood, 2016, 128, 4052-4052.	1.4	32
184	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. Blood, 2016, 128, 604-604.	1.4	1
185	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2016, 128, 69-69.	1.4	2
186	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. Blood, 2016, 128, 986-986.	1.4	3
187	Post-Operative Anticoagulation and the Incidence of Left Ventricular Assist Device Thrombosis. Blood, 2016, 128, 2620-2620.	1.4	Ο
188	A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia. Blood, 2016, 128, 5218-5218.	1.4	2
189	The Impact of Regional Cardiovascular Care Outcomes on Survival and Cardiovascular-Specific Mortality in Myelodysplastic Syndrome. Blood, 2016, 128, 5984-5984.	1.4	Ο
190	Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations. Blood, 2016, 128, 4329-4329.	1.4	0
191	Genome-Wide Analysis of a Novel Murine Model of Chronic Lymphocytic Leukemia. Blood, 2016, 128, 967-967.	1.4	0
192	Excellent Outcome of Children with Down Syndrome (DS) and Acute Lymphoblastic Leukemia (ALL) Treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols 00-001 and 05-001. Blood, 2016, 128, 761-761.	1.4	0
193	PDI Inhibition Blocks Thrombin Generation in Humans By Interfering with Platelet Factor V Activation. Blood, 2016, 128, 2628-2628.	1.4	0
194	Kinase-Activating Fusions in Pediatric High-Risk B-Lineage Acute Lymphoblastic Leukemia (ALL): a Report from the Dana-Farber Cancer Institute (DFCI) ALL Consortium. Blood, 2016, 128, 1729-1729.	1.4	0
195	Marked hyperferritinemia does not predict for HLH in the adult population. Blood, 2015, 125, 1548-1552.	1.4	170
196	Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125, 1367-1376.	1.4	747
197	Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. Blood, 2015, 125, 3668-3669.	1.4	20
198	Mitochondrial Variations in Non-Small Cell Lung Cancer (NSCLC) Survival. Cancer Informatics, 2015, 14s1, CIN.S13976.	1.9	15

#	Article	IF	CITATIONS
199	Controversial fluorescence <i>inÂsitu</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. British Journal of Haematology, 2015, 170, 694-703.	2.5	19
200	The Impact of Age and Sex in DLBCL: Systems Biology Analyses Identify Distinct Molecular Changes and Signaling Networks. Cancer Informatics, 2015, 14, CIN.S34144.	1.9	18
201	Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood, 2015, 126, 494-499.	1.4	128
202	Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2015, 33, 2205-2211.	1.6	57
203	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Modern Pathology, 2015, 28, 965-976.	5.5	31
204	Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model. Blood, 2015, 126, 212-221.	1.4	111
205	Polymorphisms of Asparaginase Pathway and Asparaginase-Related Complications in Children with Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2015, 21, 329-334.	7.0	52
206	Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells. Leukemia, 2015, 29, 1555-1563.	7.2	48
207	Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 632-638.	1.7	10
208	Biologic Activity of Autologous, Granulocyte–Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clinical Cancer Research, 2015, 21, 3178-3186.	7.0	34
209	Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 1252-1257.	1.6	57
210	A strategy to improve treatmentâ€related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. Pediatric Blood and Cancer, 2015, 62, 1395-1402.	1.5	34
211	Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncology, The, 2015, 16, 1677-1690.	10.7	193
212	Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leukemia and Lymphoma, 2015, 56, 3336-3342.	1.3	36
213	Mutations driving CLL and their evolution in progression and relapse. Nature, 2015, 526, 525-530.	27.8	868
214	Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody Genes. Cell, 2015, 163, 1124-1137.	28.9	136
215	Molecular Classification of MYC-Driven B-Cell Lymphomas by Targeted Gene Expression Profiling of Fixed Biopsy Specimens. Journal of Molecular Diagnostics, 2015, 17, 19-30.	2.8	25
216	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1713-1713.	1.4	1

#	Article	IF	CITATIONS
217	Higher Incidence of Treatment-Related Toxicities in Non-Hispanic Patients Undergoing Therapy for Newly Diagnosed Pediatric Acute Lymphoblastic Leukemia on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001. Blood, 2015, 126, 248-248.	1.4	5
218	Effectiveness of Antibacterial Prophylaxis during Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. Blood, 2015, 126, 249-249.	1.4	6
219	Homozygosity for the 2R Tandem Repeat Polymorphism in the Thymidylate Synthase (TS) Promoter Is Associated with Increased Risk for Bony Morbidity Among Children Treated for Acute Lymphoblastic Leukemia on DFCI Protocol 05-001. Blood, 2015, 126, 251-251.	1.4	3
220	Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia. Blood, 2015, 126, 2597-2597.	1.4	6
221	Ikaros Gene Deletion Significantly Predicts Relapse in Pediatric B-ALL Patients with Low End-Induction Minimal Residual Disease. Blood, 2015, 126, 2613-2613.	1.4	4
222	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. Blood, 2015, 126, 306-306.	1.4	2
223	Quantitative Clonal Dynamics Define Mechanisms of CLL Evolution in Response to Combination Chemotherapy. Blood, 2015, 126, 362-362.	1.4	4
224	Expressionof Sf3b1- K700Ein Murine B Cells Causes Pre-mRNA Splicing and Altered B Cell Differentiation and Function. Blood, 2015, 126, 366-366.	1.4	1
225	Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3765-3765.	1.4	3
226	Results of a Multicenter Pilot Investigation of Bone Marrow Transplantation in Adults with Sickle Cell Disease (STRIDE). Blood, 2015, 126, 543-543.	1.4	8
227	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood, 2015, 126, 80-80.	1.4	38
228	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
229	Comprehensive Bulk and Single Cell Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 2906-2906.	1.4	2
230	The Impact of Insurance Status at Diagnosis on Overall Survival in Chronic Myeloid Leukemia: A Population-Based Analysis. Blood, 2015, 126, 631-631.	1.4	0
231	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. Blood, 2015, 126, 176-176.	1.4	4
232	Comparison of Age at Diagnosis, Cytogenetic Risk, and Overall Survival Between Acute Myeloid Leukemia Patients of White and South Asian Race/Ethnicity in the United States. Blood, 2015, 126, 3753-3753.	1.4	0
233	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3922-3922.	1.4	Ο
234	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. Blood, 2015, 126, 2655-2655.	1.4	0

#	Article	IF	CITATIONS
235	The End of Life for Patients with Acute Myeloid Leukemia (AML)- a Single Center Experience. Blood, 2015, 126, 3318-3318.	1.4	2
236	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. Blood, 2015, 126, 1304-1304.	1.4	0
237	The Impact of Age and Sex in DLBCL: Determination of Biologic Dynamics and Delineation of Inter-Connected Signaling Networks Via a Systems Biology Analysis. Blood, 2015, 126, 2672-2672.	1.4	0
238	Loss of function <i>tp53</i> mutations do not accelerate the onset of <i>myc</i> â€induced Tâ€eell acute lymphoblastic leukaemia in the zebrafish. British Journal of Haematology, 2014, 166, 84-90.	2.5	16
239	Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia. Cancer Cell, 2014, 26, 813-825.	16.8	323
240	Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes. New England Journal of Medicine, 2014, 371, 2488-2498.	27.0	3,474
241	Emergence, Involution, and Progression to Carcinoma of Mutant Clones in Normal Endometrial Tissues. Cancer Research, 2014, 74, 2796-2802.	0.9	48
242	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood, 2014, 124, 453-462.	1.4	286
243	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 2691-2698.	1.6	359
244	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nature Communications, 2014, 5, 3469.	12.8	171
245	Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nature Genetics, 2014, 46, 618-623.	21.4	117
246	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	27.8	708
247	Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood, 2014, 124, 1089-1098.	1.4	65
248	Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study. Journal of Clinical Oncology, 2014, 32, 1792-1796.	1.6	45
249	A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leukemia Research, 2014, 38, 430-434.	0.8	23
250	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. Blood, 2014, 123, 4101-4110.	1.4	63
251	TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood, 2014, 124, 2705-2712.	1.4	486
252	NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. Leukemia, 2013, 27, 2077-2081.	7.2	57

#	Article	IF	CITATIONS
253	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Cell, 2013, 152, 714-726.	28.9	1,202
254	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factorâ€bearing microparticles: a randomized ontrolled phase II trial (the Microtec) Tj ETQq0	0 02gBT /(Dve rlis ck 10 Tf
255	Postinduction Dexamethasone and Individualized Dosing of <i>Escherichia Coli</i> L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Iournal of Clinical Oncology. 2013. 31. 1202-1210.	1.6	274
256	SYK Inhibition Modulates Distinct PI3K/AKT- Dependent Survival Pathways and Cholesterol Biosynthesis in Diffuse Large B Cell Lymphomas. Cancer Cell, 2013, 23, 826-838.	16.8	152
257	Reconstructing a Genotype-Phenotype Map In Chronic Lymphocytic Leukemia. Blood, 2013, 122, 2857-2857.	1.4	1
258	Ofatumumab As Initial Therapy For Indolent B Cell Lymphomas: A Phase II Trial. Blood, 2013, 122, 3062-3062.	1.4	14
259	Clonal Evolution In Patients With Chronic Lymphocytic Leukemia (CLL) Developing Resistance To BTK Inhibition. Blood, 2013, 122, 866-866.	1.4	22
260	Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency. Leukemia, 2012, 26, 2069-2078.	7.2	64
261	Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2012, 18, 3791-3802.	7.0	76
262	Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML. Cell, 2012, 151, 344-355.	28.9	294
263	Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma. Cancer Cell, 2012, 22, 359-372.	16.8	179
264	Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. Journal of Thrombosis and Haemostasis, 2012, 10, 1449-1451.	3.8	24
265	Comparison of Minimal Residual Disease Detection Using High-Throughput Sequencing and Allele-Specific Oligonucleotide PCR Methods in Pediatric B-Lineage Acute Lymphoblastic Leukemia Blood, 2012, 120, 2532-2532.	1.4	1
266	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia Blood, 2012, 120, 2875-2875.	1.4	1
267	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. Blood, 2012, 120, 311-311.	1.4	3
268	Intensified Chemotherapy Regimen for Very High Risk Childhood B-Precursor Acute Lymphoblastic Leukemia (B-ALL): Results From Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05–01. Blood, 2012, 120, 3563-3563.	1.4	13
269	Somatic Mutation As a Mechanism of Wnt/ \hat{I}^2 -Catenin Pathway Activation in CLL. Blood, 2012, 120, 559-559.	1.4	0
270	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1470-1470.	1.4	1

#	Article	IF	CITATIONS
271	Systematic Identification of Personal Mutated Tumor-Specific Neoantigens in CLL. Blood, 2012, 120, 954-954.	1.4	0
272	Association of Baseline Body Mass Index (BMI) with Overall Survival Among Patients Over Age 60 with Acute Myeloid Leukemia (AML). Blood, 2012, 120, 1484-1484.	1.4	0
273	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. Blood, 2012, 120, 1534-1534.	1.4	0
274	Galectin-1 Serum Levels Reflect Tumor Burden and Adverse Clinical Features in Hodgkin Lymphoma. Blood, 2012, 120, 51-51.	1.4	0
275	Deregulation of TLR2-JMJD3 Innate Immunity Signaling, Including a Rare TLR2 SNP As a Potential Somatic Mutation, in Myelodysplastic Syndromes (MDS). Blood, 2012, 120, 1700-1700.	1.4	0
276	<i>SF3B1</i> and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2011, 365, 2497-2506.	27.0	1,021
277	The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. European Journal of Cancer, 2011, 47, 1373-1379.	2.8	99
278	Clinical Effect of Point Mutations in Myelodysplastic Syndromes. New England Journal of Medicine, 2011, 364, 2496-2506.	27.0	1,444
279	The frequency and management of asparaginaseâ€related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Danaâ€Farber Cancer Institute consortium protocols. British Journal of Haematology, 2011, 152, 452-459.	2.5	216
280	Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. Journal of Experimental Medicine, 2011, 208, 1595-1603.	8.5	104
281	Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL. Blood, 2011, 118, 284-284.	1.4	1
282	Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. Blood, 2011, 118, 2865-2865.	1.4	3
283	Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium. Blood, 2011, 118, 291-291.	1.4	5
284	A Comparative Retrospective Survey of Reinduction Chemotherapy Regimens for Acute Myeloid Leukemia (AML) in First Relapse: A Single-Institution Experience. Blood, 2011, 118, 4273-4273.	1.4	1
285	Retrospective Analysis of Thrombocytopenia in Relapsed Multiple Myeloma Patients. Blood, 2011, 118, 5073-5073.	1.4	1
286	Randomized Comparison of IV PEG and IM E. Coli Asparaginase in Children and Adolescents with Acute Lymphoblastic Leukemia: Results of the DFCI ALL Consortium Protocol 05-01. Blood, 2011, 118, 874-874.	1.4	6
287	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 465-465.	1.4	0
288	Regadenoson, An Adenosine 2A Receptor Agonist, Is Safe and Inhibits Invariant NKT Cells in Sickle Cell Disease. Blood, 2011, 118, 849-849.	1.4	0

#	Article	IF	CITATIONS
289	Treatment of Chronic Lymphocytic Leukemia Patients with Lenalidomide Induces Down-Regulation of miR342-3p Associated with Over-Expression of Tumor Suppressor RASSF4,. Blood, 2011, 118, 3885-3885.	1.4	0
290	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. Blood, 2011, 118, 463-463.	1.4	0
291	MicroRNA Profiling in Patients with CLL B Cells Expressing the Unmutated IGHV1-69 Gene. Blood, 2011, 118, 2846-2846.	1.4	0
292	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1438-1438.	1.4	0
293	Clinical Significance of Coagulation Studies in Predicting Response to Recombinant Factor VIIa in Cardiac Surgery Patients. Blood, 2011, 118, 4351-4351.	1.4	0
294	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood, 2010, 116, 3268-3277.	1.4	1,122
295	T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation. Cancer Cell, 2010, 18, 353-366.	16.8	141
296	Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncology, The, 2010, 11, 950-961.	10.7	377
297	Absence of Biallelic <i>TCR</i> γ Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2010, 28, 3816-3823.	1.6	93
298	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood, 2009, 114, 647-650.	1.4	414
299	The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols Blood, 2009, 114, 3073-3073.	1.4	1
300	Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01 Blood, 2009, 114, 321-321.	1.4	14
301	MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 1285-1290.	7.1	235
302	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3005-3010.	7.1	604
303	Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane. Journal of Clinical Oncology, 2008, 26, 1106-1111.	1.6	111
304	Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood, 2007, 109, 896-904.	1.4	362
305	Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood, 2007, 110, 1607-1611.	1.4	126
306	Large Regions of Uniparental Disomy (UPD) Establish Clonal Hematopoietic Stem Cell Selection in a Subset of Myelodysplastic Syndrome (MDS) Patients with Normal Bone Marrow Cell Karyotypes Blood, 2007, 110, 120-120.	1.4	4

#	Article	IF	CITATIONS
307	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas Blood, 2007, 110, 1358-1358.	1.4	2
308	Increased Risk of Skeletal Toxicity and Infection in Children 10 Years or Older Treated for Acute Lymphoblastic Leukemia (ALL) with Dexamethasone: Results from the DFCI ALL Consortium Blood, 2007, 110, 849-849.	1.4	2
309	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma Blood, 2007, 110, 2331-2331.	1.4	6
310	MDM2 polymorphism and recurrence-free and overall survival in early stage non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2006, 24, 7221-7221.	1.6	1
311	Inhibiting TNFα with etanercept in relapsed/refractory follicular lymphoma. Journal of Clinical Oncology, 2006, 24, 17525-17525.	1.6	0
312	Emi1 Is Required for Normal Cell Cycle Progression in Zebrafish Myelopoiesis and Likely Functions as a Haploinsufficient Tumor Suppressor on Chromosome 6q in Human Leukmias Blood, 2006, 108, 1405-1405.	1.4	0
313	Engineered Expression of JAK2V617F Drastically Changes the Response of Progenitor Cells to Erythropoietin and Partially Mimics the Polycythemia Expression Signature Blood, 2006, 108, 3597-3597.	1.4	0
314	Intravenous PEG Asparaginase during Remission Induction for Childhood ALL Blood, 2006, 108, 1854-1854.	1.4	1
315	Bcl2 Accelerates Onset but Not Progression of MYC-Induced T-Cell Leukemia in Transgenic Zebrafish Blood, 2006, 108, 1829-1829.	1.4	0
316	Pharmacodynamics and Tolerability of Twice-Weekly Erwinia Asparaginase after E. coli Asparaginase Allergy in Children with ALL Blood, 2006, 108, 1857-1857.	1.4	2
317	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse Blood, 2006, 108, 3041-3041.	1.4	0
318	Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. Journal of Clinical Investigation, 2005, 115, 1797-1805.	8.2	259
319	Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood, 2005, 105, 1851-1861.	1.4	778
320	HOXB9 Is Aberrantly Expressed in Blast Cells in a Subset of Acute Myeloid Leukemia Patients and Supports Proliferation of AML Cell Lines. Blood, 2005, 106, 1613-1613.	1.4	1
321	Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate Blood, 2005, 106, 2782-2782.	1.4	4
322	Expression of T Cell Co-Stimulator (ICOS) and Its Ligand and Disease Progression in B-Cell Chronic Lymphocytic Leukemia Blood, 2005, 106, 2943-2943.	1.4	1
323	The <i>ERCC1 C8092A</i> polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation. Journal of Clinical Oncology, 2004, 22, 2014-2014.	1.6	0
324	The <i>ERCC1 C8092A</i> polymorphism and grade III/IV gastrointestinal (GI) toxicity in non-small cell lung cancer (NSCLC) patients treated with chemoradiation. Journal of Clinical Oncology, 2004, 22, 2014-2014.	1.6	0

DONNA NEUBERG

#	Article	IF	CITATIONS
325	Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell, 2002, 1, 75-87.	16.8	1,024
326	Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 1999, 17, 3128-3135.	1.6	180
327	Using recursive partitioning for exploration and followâ€up of linkage and association analyses. Genetic Epidemiology, 1999, 17, S391-6.	1.3	6
328	Toxicity and Efficacy of Defined Doses of CD4+ Donor Lymphocytes for Treatment of Relapse After Allogeneic Bone Marrow Transplant. Blood, 1998, 91, 3671-3680.	1.4	304
329	Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood, 1998, 91, 3671-80.	1.4	75
330	Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion Journal of Clinical Investigation, 1997, 100, 855-866.	8.2	94
331	Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. Blood, 1994, 84, 3974-3979.	1.4	51
332	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood, 1993, 81, 3449-3457.	1.4	318
333	Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood, 1993, 81, 3449-3457.	1.4	7
334	A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. , 0, .		2